Study summary

Inebilizumab improved daily function in AChR and MuSK myasthenia

MINT trial · 238 people, phase 3 · Published April 2025, New England Journal of Medicine; FDA approved December 2025

-4.2point MG-ADL change with inebilizumab, vs -2.2 with placebo

What was tested

Inebilizumab, an antibody that removes CD19 B cells, against placebo in generalized myasthenia gravis with AChR or MuSK antibodies.

What they found

Daily-living (MG-ADL) scores improved 4.2 points vs 2.2 with placebo at 26 weeks.
Benefit in MuSK-positive patients held through 52 weeks in later analyses.

What it means

A twice-yearly infusion option, including for MuSK-positive disease, which has fewer choices.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.